MX2016008445A - Derivados de pirazolo [1,5-a] piridina y metodos para su uso. - Google Patents

Derivados de pirazolo [1,5-a] piridina y metodos para su uso.

Info

Publication number
MX2016008445A
MX2016008445A MX2016008445A MX2016008445A MX2016008445A MX 2016008445 A MX2016008445 A MX 2016008445A MX 2016008445 A MX2016008445 A MX 2016008445A MX 2016008445 A MX2016008445 A MX 2016008445A MX 2016008445 A MX2016008445 A MX 2016008445A
Authority
MX
Mexico
Prior art keywords
pyrazolo
pyridine derivatives
methods
pyridine
derivatives
Prior art date
Application number
MX2016008445A
Other languages
English (en)
Inventor
L Hudkins Robert
L Zulli Allison
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of MX2016008445A publication Critical patent/MX2016008445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se dirige a derivados de pirazolo [1,5-a]piridina y a su uso como inhibidores de AXL y METc cinasa.
MX2016008445A 2013-12-26 2014-12-18 Derivados de pirazolo [1,5-a] piridina y metodos para su uso. MX2016008445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26
PCT/US2014/071040 WO2015100117A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Publications (1)

Publication Number Publication Date
MX2016008445A true MX2016008445A (es) 2016-10-28

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008445A MX2016008445A (es) 2013-12-26 2014-12-18 Derivados de pirazolo [1,5-a] piridina y metodos para su uso.

Country Status (22)

Country Link
US (2) US9914731B2 (es)
EP (2) EP3087070B1 (es)
JP (1) JP2017500362A (es)
KR (1) KR20160110390A (es)
CN (1) CN106029661B (es)
AU (1) AU2014370186A1 (es)
BR (1) BR112016015057A2 (es)
CA (1) CA2934667A1 (es)
CL (1) CL2016001604A1 (es)
DK (1) DK3087070T3 (es)
EA (2) EA029757B1 (es)
ES (1) ES2654931T3 (es)
HU (1) HUE037579T2 (es)
IL (1) IL246311A0 (es)
MX (1) MX2016008445A (es)
NO (1) NO3014707T3 (es)
PH (1) PH12016501232A1 (es)
PL (1) PL3087070T3 (es)
PT (1) PT3087070T (es)
SG (1) SG11201605207PA (es)
SI (1) SI3087070T1 (es)
WO (1) WO2015100117A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6816100B2 (ja) * 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
EP3558991A2 (en) * 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
CN111372925B (zh) * 2017-11-24 2022-09-02 南京明德新药研发有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3842425A4 (en) * 2018-08-24 2022-05-18 Nanjing Transthera Biosciences Co., Ltd. NOVEL QUINOLINE DERIVATIVE INHIBITORS
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences CONNECTION WITH AXL AND C-MET KINASE INHIBITORY ACTIVITY, THEIR PREPARATION AND USE
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JPWO2023286719A1 (es) * 2021-07-13 2023-01-19
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7723330B2 (en) * 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
KR20090090336A (ko) * 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
WO2010017047A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
MX336996B (es) * 2009-12-31 2016-02-09 Hutchison Medipharma Ltd Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso.
EP2678338B1 (en) * 2011-02-25 2015-09-09 Novartis AG Pyrazolo[1,5-a]pyridines as trk inhibitors
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
CA2844588A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
MX2014002990A (es) * 2011-09-19 2014-05-21 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
BR112014011548A2 (pt) * 2011-11-14 2017-05-09 Cephalon Inc composto
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
BR112016015057A2 (pt) 2017-08-08
PL3087070T3 (pl) 2018-03-30
EP3309160A1 (en) 2018-04-18
HUE037579T2 (hu) 2018-09-28
EA201890061A2 (ru) 2018-05-31
EA201890061A3 (ru) 2018-09-28
ES2654931T3 (es) 2018-02-15
DK3087070T3 (en) 2017-12-04
EP3087070B1 (en) 2017-11-08
EP3087070A1 (en) 2016-11-02
AU2014370186A2 (en) 2016-07-21
PH12016501232A1 (en) 2016-08-15
SI3087070T1 (en) 2018-01-31
EA029757B1 (ru) 2018-05-31
NO3014707T3 (es) 2018-01-06
SG11201605207PA (en) 2016-07-28
US9914731B2 (en) 2018-03-13
PT3087070T (pt) 2018-01-30
CL2016001604A1 (es) 2017-05-26
US20180148447A1 (en) 2018-05-31
WO2015100117A1 (en) 2015-07-02
IL246311A0 (en) 2016-08-02
CA2934667A1 (en) 2015-07-02
KR20160110390A (ko) 2016-09-21
CN106029661A (zh) 2016-10-12
AU2014370186A1 (en) 2016-07-14
EA201691164A1 (ru) 2016-12-30
JP2017500362A (ja) 2017-01-05
US20160318929A1 (en) 2016-11-03
CN106029661B (zh) 2017-11-03

Similar Documents

Publication Publication Date Title
PH12016501232A1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
HRP20190152T1 (hr) Kombinacija pirolo[2,3-d]pirimidinskih derivata s jednim ili više dodatnih sredstava kao inhibitori kinaza srodnih janus kinazi (jak)
LT3429591T (lt) Pakeistojo tieno[2,3-d]pirimidino dariniai kaip menino-mll inhibitoriai ir jų panaudojimo būdai
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
MY185392A (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
HK1219101A1 (zh) 作為 激酶抑制劑的 三唑並 吡啶的衍生物
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
NZ717825A (en) Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ